Abstract
Duchenne muscular dystrophy (DMD), an X-linked childhood-onset muscular dystrophy caused by loss of the protein dystrophin, can be associated with neurodevelopmental, emotional and behavioural problems. A DMD mouse model also displays a neuropsychiatric phenotype, including increased startle responses to threat which normalise when dystrophin is restored in the brain.
We hypothesised that startle responses may also be increased in humans with DMD, which would have potential translational therapeutic implications. To investigate this, we first designed a novel discrimination fear-conditioning task and tested it in six healthy volunteers, followed by male DMD (n=11) and Control (n=9) participants aged 7-12 years. The aims of this methodological task development study were to: i) confirm the task efficacy; ii) optimise data processing procedures; iii) determine the most appropriate outcome measures.
In the task, two neutral visual stimuli were presented: one ‘safe’ cue presented alone; one ‘threat’ cue paired with a threat stimulus (aversive noise) to enable conditioning of physiological startle responses (skin conductance response, SCR, and heart rate). Outcomes were the unconditioned physiological startle responses to the initial threat, and retention of conditioned responses in the absence of the threat stimulus.
We present the protocol development and optimisation of data processing methods based on empirical data. We found that the task was effective in producing significantly higher physiological startle SCR in reinforced ‘threat’ trials compared to ‘safe’ trials (P<.001). Different data extraction methods were compared and optimised, and the optimal sampling window was derived empirically. SCR amplitude was the most effective physiological outcome measure when compared to SCR area and change in heart rate, with the best profile on data processing, the least variance, successful conditioned response retention (P=.01) and reliability assessment in test-retest analysis (rho=.86). The definition of this novel outcome will allow us to study this response in a DMD population.
Competing Interest Statement
Francesco Muntoni has received grants, speaker and consultancy honoraria from Sarepta Therapeutics, Avexis, PTC Therapeutics, Roche, Biogen, Dyne Therapeutics, Novartis and Pfizer. David Skuse has current grant funding from the Medical Research Council (UK), Sarepta Therapeutics, the European Research Council, and the Patrick Paul Foundation. William Mandy is supported by the National Institute of Health Research, Autistica, the Dunhill Medical Trust, the Medical Research Council and the European Research Council. Neil Harrison has received consulting fees from Janssen and GSK. The remaining authors report no competing interests.
Funding Statement
This study was supported by Great Ormond Street Hospital Childrens Charity (Grant no. V0119). KM was also supported by the Medical Research Council (MRC) via the MRC Centre for Neuromuscular Diseases grant no. MR/K000608/1 (Institute of Neurology, University College London). The partial support of EUH2020 grant 83245 Brain Involvement iN Dystrophinopathies to UCL is also acknowledged.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All study participants and parents/guardians (where applicable) were given age-appropriate participant information leaflets in advance of the study procedures, which had been approved by the relevant ethics committees (see below). All participants +/- parents/guardians gave written informed consent (assent for child participants) prior to taking part in the study. Ethical approval was granted by the following bodies: First stage of task development (healthy volunteer study): UCL Research Ethics Committee (REC) (Project ID no. 9639/001). Second stage of task development (clinical DMD population and aged-matched controls aged 7-12 years): Health Research Authority (HRA), London Bridge Research Ethics Committee (18.LO.1575).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The authors confirm that the data supporting the findings of this study are available within the article. In view of the rarity of DMD and that genotype data is included, only aggregated data will be made available on reasonable request.
- Abbreviations
- ASD
- Autism spectrum disorder
- CS
- Conditioned stimulus
- DMD
- Duchenne muscular dystrophy
- ECG
- Electrocardiogram
- EDA
- Electrodermal activity
- EEG
- Electroencephalography
- fMRI
- Functional magnetic resonance imaging
- GABA
- Gamma amino butyric acid
- GOSH
- Great Ormond Street Hospital for Children
- HR
- Heart rate
- ITI
- Inter-trial interval
- LOA
- Limits of agreement
- MEG
- Magnetoencephalography
- MRI
- Magnetic resonance imaging
- SCL
- Skin conductance level
- SCR
- Skin conductance response
- TTP
- Time-to-peak
- UCL
- University College London
- UCL GOS ICH
- UCL Great Ormond Street Institute of Child Health
